Clinical Trials Logo

Clinical Trial Summary

The primary purpose of this study was to describe the time to tolerization (i.e., ITI success) with rFVIIIFc in participants within a maximum of 48 weeks (12 months) of ITI treatment.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03093480
Study type Interventional
Source Sanofi
Contact
Status Completed
Phase Phase 4
Start date December 8, 2017
Completion date February 16, 2021

See also
  Status Clinical Trial Phase
Completed NCT00231751 - The Malmö International Brother Study (MIBS) N/A
Completed NCT00221195 - Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors Phase 2/Phase 3
Terminated NCT02484638 - Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors Phase 2/Phase 3
Terminated NCT00212472 - International Immune Tolerance Study N/A
Withdrawn NCT03002480 - Individualizing Hemophilia Bypassing Agent Therapy Utilizing Thromboelastography N/A
Completed NCT02448680 - A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa Phase 3
Active, not recruiting NCT01105546 - rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors Phase 2
Completed NCT02020369 - A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX Phase 3